PERSONAL
PROFESSIONAL
PHILANTHROPY
CONTACT
Home
>>
Professional Posts
Pete Petit's Professional Posts
2016
MiMedx Files Lawsuits Against Two Additional Former Sales Employees For Breach Of Contractual Obligations
MiMedx Announces Preliminary Investigation Findings
MiMedx EpiFix Receives Coverage From Aetna
MiMedx 2017 Guidance Forecasts Revenue Growth In Excess Of 21% And Operating Earnings Growth In Excess Of 90%
MiMedx Comments on Meritless Lawsuit
MiMedx Applauds Passage of 21st Century Cures Act
MiMedx Announces U.S. Pharmacopeia Monograph For dHACM Allografts Has Published
MiMedx Announces Third Quarter 2016 Results
MiMedx Is Grand Sponsor Of Desert Foot 2016
MiMedx Third Quarter 2016 Revenue Exceeds Upper End of Guidance
Advances In Regenerative Medicine With MiMedx EpiFix® And AmnioFix® To Be Presented At SAWC Fall Meeting
MiMedx at the 5th Congress of World Union Wound Healing Societies
MiMedx Urges FDA To Reconsider Draft Guidances During Hearing
Scientific Study Confirms How MiMedx dHACM Allografts Effectively Promote Wound Repair
MiMedx Reaffirms Q3 and Full Year 2016 Guidance
MiMedx Announces Nationwide Launch of AmnioFill™
MiMedx Provides Update On Key Clinical Trials
MiMedx Awarded Six New U.S. Patents with Five Awarded for its Amniotic Membrane Allografts and One Awarded for its CollaFix™ Technology
MiMedx Amniotic Allografts Are Terminally Sterilized To Enhance Safety Related To Microbiological And Viral Transmission
MiMedx announces ruling from PTAB on its embossment patent
MiMedx Announces Second Quarter 2016 Results
MiMedx Announces Nationwide Launch of New Ambient Temperature Version of OrthoFlo
MiMedx Second Quarter Of 2016 Revenue Exceeds Upper End Of Guidance Range
MiMedx Adds New Executive
MiMedx Reaches Settlement With Medline Industries And Liventa Bioscience For Certain Claims
Independent Clinical Case Series Demonstrates MiMedx dHACM, Along With Split Thickness Skin Grafts, Is Effective In Limb Salvage
MiMedx Files Lawsuit Against Osiris For False And Misleading Representations
MiMedx Provides Reminder of May 18th Annual Shareholders Meeting
MiMedx Comments on Flawed Osiris Data Review
MiMedx Announces First Quarter 2016 Results
MiMedx Announces Release Date for 2016 First Quarter Results
The Impact of MiMedx EpiFix® to be Presented at SAWC Conference
MiMedx Announces First Quarter of 2016 Revenue Results
MiMedx Supports FDA's Decision to Postpone April 13th Hearing on Draft Guidance Documents
MiMedx Announces 2015 Record Results
MiMedx Announces Release Date For 2015 Full Year Results
MiMedx Completes Acquisition Of Stability Biologics
MiMedx Exceeds Fourth Quarter And Full Year 2015 Revenue Consensus
MiMedx Signs Definitive Agreement To Acquire Stability Biologics
MiMedx Receives Certificate From FDA Allowing The Export Of MiMedx Allografts